Development of a potent recombinant antibody against theSARS-CoV-۲ by in-depth immunoinformatics study
محل انتشار: بیست و سومین کنگره بین المللی میکروب شناسی ایران
سال انتشار: 1401
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 74
نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
MEDISM23_456
تاریخ نمایه سازی: 16 مهر 1401
چکیده مقاله:
Background and Aim : As good candidates against the coronavirus infection, antibodies havebeen attracted high attentions. Accordingly, the current study was designed to harness the powerof bioinformatics study for the development of a potent recombinant antibody against the SARSCoV-۲ spike's RBD.Methods : The prediction of B-cell epitopes (BCEs) in the RBD was done based on the multimethodapproaches. Following the primary screening of antibodies according to their binding toBCEs, the comprehensive screening was performed based on the various criteria. Thereafter, usingthis hierarchal approach, one antibody was selected. A serine-glycine linker was used to link thevariable part of light and heavy chain. The construct was engineered by addition of pelB signalsequence to direct this single-chain fragment variable (scFv) antibody to the periplasmic space ofE. coli.Results : Among the various hit antibodies in our library, only one lead antibody met the variouscriteria and its good in silico reaction was confirmed with the verified/predicted BCEs. Moreover,the results did not show any interaction between paratope-mutable RBD residues.Conclusion : As one of limited research in the field of immunoinformatics, the current study couldbe considered as a platform for design the neutralizing antibodies against the SARS-CoV-۲ andother infectious agents, too.
کلیدواژه ها:
نویسندگان
Fatemeh Yaghoobizadeh
Department of Biology, Shahid Chamran University of Ahvaz, Ahvaz, Khouzestan, Iran
Mohammad Roayaei Ardakani
Department of Biology, Shahid Chamran University of Ahvaz, Ahvaz, Khouzestan, Iran
Mohammad Mehdi Ranjbar
Razi Vaccine and Serum Research Institute, Karaj, Alborz, Iran.
Mohammad Khosravi
Department of Pathobiology, Shahid Chamran University of Ahvaz, Ahvaz, Khouzestan, Iran.
Hamid Galehdari
Department of Biology, Shahid Chamran University of Ahvaz, Ahvaz, Khouzestan, Iran